Southern Acids (M) Berhad, an investment holding company, engages in the manufacture and marketing of oleochemical products.
No risks detected for SAB from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||RM3.90|
|52 Week High||RM3.60|
|52 Week Low||RM4.20|
|1 Month Change||0.52%|
|3 Month Change||3.72%|
|1 Year Change||5.41%|
|3 Year Change||2.09%|
|5 Year Change||-2.01%|
|Change since IPO||-18.07%|
Recent News & Updates
If You Like EPS Growth Then Check Out Southern Acids (M) Berhad (KLSE:SAB) Before It's Too Late
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
|SAB||MY Chemicals||MY Market|
Return vs Industry: SAB underperformed the MY Chemicals industry which returned 39.9% over the past year.
Return vs Market: SAB matched the MY Market which returned 6.1% over the past year.
Stable Share Price: SAB is not significantly more volatile than the rest of MY stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: SAB's weekly volatility (6%) has been stable over the past year.
About the Company
Southern Acids (M) Berhad, an investment holding company, engages in the manufacture and marketing of oleochemical products. It operates through four segments: Oleochemical, Healthcare, Milling & Estate, and Investments & Services. The company manufactures and markets fatty acids and glycerine for use in various applications, including personal care, cleaning agents, and food products.
Is Southern Acids (M) Berhad undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SAB (MYR3.9) is trading above our estimate of fair value (MYR0.75)
Significantly Below Fair Value: SAB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SAB is good value based on its PE Ratio (14.3x) compared to the MY Chemicals industry average (16.7x).
PE vs Market: SAB is good value based on its PE Ratio (14.3x) compared to the MY market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SAB is good value based on its PB Ratio (0.8x) compared to the MY Chemicals industry average (1.3x).
How is Southern Acids (M) Berhad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Materials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Southern Acids (M) Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Southern Acids (M) Berhad performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SAB has high quality earnings.
Growing Profit Margin: SAB's current net profit margins (5%) are higher than last year (4.8%).
Past Earnings Growth Analysis
Earnings Trend: SAB's earnings have grown by 0.5% per year over the past 5 years.
Accelerating Growth: SAB's earnings growth over the past year (16.7%) exceeds its 5-year average (0.5% per year).
Earnings vs Industry: SAB earnings growth over the past year (16.7%) underperformed the Chemicals industry 70.8%.
Return on Equity
High ROE: SAB's Return on Equity (6.7%) is considered low.
How is Southern Acids (M) Berhad's financial position?
Financial Position Analysis
Short Term Liabilities: SAB's short term assets (MYR428.5M) exceed its short term liabilities (MYR69.3M).
Long Term Liabilities: SAB's short term assets (MYR428.5M) exceed its long term liabilities (MYR27.5M).
Debt to Equity History and Analysis
Debt Level: SAB's debt to equity ratio (0.6%) is considered satisfactory.
Reducing Debt: SAB's debt to equity ratio has increased from 0% to 0.6% over the past 5 years.
Debt Coverage: SAB's debt is well covered by operating cash flow (1062.9%).
Interest Coverage: SAB's interest payments on its debt are well covered by EBIT (129.3x coverage).
What is Southern Acids (M) Berhad current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SAB's dividend (1.28%) isn’t notable compared to the bottom 25% of dividend payers in the MY market (1.51%).
High Dividend: SAB's dividend (1.28%) is low compared to the top 25% of dividend payers in the MY market (4.09%).
Stability and Growth of Payments
Stable Dividend: SAB's dividends per share have been stable in the past 10 years.
Growing Dividend: SAB's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (18.3%), SAB's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nick Low (42 yo)
Dr. Kok Thye Low , also known as Nick, has been Managing Director and Director of Southern Acids M Bhd since July 2015. Dr. Low served as a Director In-Lead of Oleochemical and Health Care Divisions at Sou...
CEO Compensation Analysis
Compensation vs Market: Nick's total compensation ($USD174.72K) is above average for companies of similar size in the MY market ($USD124.03K).
Compensation vs Earnings: Nick's compensation has been consistent with company performance over the past year.
Experienced Management: SAB's management team is seasoned and experienced (9.3 years average tenure).
Experienced Board: SAB's board of directors are considered experienced (8.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Southern Acids (M) Berhad's employee growth, exchange listings and data sources
- Name: Southern Acids (M) Berhad
- Ticker: SAB
- Exchange: KLSE
- Founded: 1980
- Industry: Commodity Chemicals
- Sector: Materials
- Market Cap: RM534.043m
- Shares outstanding: 136.93m
- Website: https://www.southernacids.com
Number of Employees
- Southern Acids (M) Berhad
- Centro Tower
- Level 29
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/17 11:02|
|End of Day Share Price||2021/09/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.